Biopharma · FDA Approvals · Stock
CV CapsoVision
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 3…
Assets on file: AI Highlights
Catalyst calendar
Dated catalysts for CV, including recently decided ones.
Nothing scheduled in this window.
Recent first-hand events
Every first-hand event for CV, newest first.
CVCapsoVisionCapsoVision Receives FDA Clearance for AI Highlights Tool for CapsoCam Plus
The FDA cleared AI Highlights, an AI-assisted reading tool that marks suspected abnormal lesions to reduce review time for small bowel capsule endoscopy studies performed for suspected bleeding in adults and pediatric patients over two years old. The tool integrates with CapsoView and CapsoCloud software for the CapsoCam Plus system and is not intended to replace physician interpretation.
CVCapsoVisionCapsoVision anticipates FDA clearance of AI Highlights by end of Q3 2026
The company now expects FDA clearance of AI Highlights, its AI-assisted reading feature for CapsoCam Plus, by the end of Q3 2026, with U.S. commercial launch to follow shortly thereafter. This timeline replaces any prior guidance and sets the next regulatory milestone for the product.
Peers by market cap
Companies in the same sector closest to CV in market value.
FENCFennec PharmaceuticalsMarket cap $359.1M · 1 tracked drug · 1 upcoming catalyst
CYPHCypherpunk TechnologiesMarket cap $356.7M
OBIOOrchestra BioMedMarket cap $355.2M · 2 tracked drugs
KYTXKyvernaMarket cap $350.7M · 1 tracked drug · 3 upcoming catalysts
EBSEmergent BioSolutionsMarket cap $349.2M · 3 tracked drugs
RLMDRelmadaMarket cap $381.9M · 1 tracked drug · 6 upcoming catalysts
AVTXAvalo TherapeuticsMarket cap $384.5M · 2 tracked drugs
CAPRCapricorMarket cap $385.5M · 1 tracked drug · 1 upcoming catalyst